The public meeting will be held on Wednesday August 27, 2025 and Thursday August 28, 2025, from 10 a.m. to 1 p.m. The meeting agenda, biographies, additional materials, and any other updates will also be posted to this website as they become available.
Similar Posts
Ongoing | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.Abdallah Candies Issues a Voluntary Recall of Pecan Caramel Clusters Due to Undeclared, Mislabeled Allergens
Abdallah Candies is voluntarily recalling a specific lot of Pecan Caramel Clusters, due to a mislabeled allergen. Product contains Cashews that were not listed on the product label. Product was sold and distributed exclusively to Lunds & Byerlys, as a private label, sold in the state of Minnesota.CDER Staff Member Shares Her Experience in a Breast Cancer Clinical Trial
She was overwhelmed, but she felt the trial was her best chance for a successful outcome.Northern VA Compounders PLLC, dba Akina Pharmacy – 671700 – 04/12/2024
Compounding Pharmacy/Adulterated Drug ProductsCoronavirus Aid, Relief, and Economic Security Act (CARES Act) Drug Shortage Mitigation Efforts
The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law on March 27, 2020 to aid response efforts and ease the economic impact of COVID-19.GDUFA Paid Facilities List
This list contains GDUFA facility payments received by the Agency. Data are extract from the User Fee System and GDUFA Facility User Fee Coversheets. The following table explains the terms used in the list: